Abstract
Viral infections are a major cause of infectious diseases worldwide. Inflammation and the immune system are the major host defenses against these viral infection. Prostaglandin E2 (PGE2), an eicosanoid generated by cyclooxygenases, has been shown to modulate inflammation and the immune system by regulating the expression/concentration of cytokines. The effect of PGE2 on viral infection and replication is cell type- and virus-family-dependent. The host immune system can be modulated by PGE2, with regards to immunosuppression, inhibition of nitrogen oxide (NO) production, inhibition of interferon (IFN) and apoptotic pathways, and inhibition of viral receptor expression. Furthermore, PGE2 can play a role in viral infection directly by increasing the production and release of virions, inhibiting viral binding and replication, and/or stimulating viral gene expression. PGE2 may also have a regulatory role in the induction of autoimmunity and in signaling via Toll-like receptors. In this review the known effects of PGE2 on the pathogenesis of various infections caused by herpes simplex virus, rotavirus, influenza A virus and human immunodeficiency virus as well the therapeutic potential of PGE2 are discussed.
Introduction
Viruses are small infectious agents that cause disease in all forms of life (Koonin et al., ). Based on their genomic material, they are classified as double-stranded (ds) DNA viruses, single-stranded (ss) DNA viruses, dsRNA viruses, (+)ssRNA viruses, (−)ssRNA viruses, ssRNA- reverse transcriptase (RT) viruses, and dsDNA-RT viruses (Baltimore, ).
To protect themselves from infection by viruses, hosts evolved immune systems (Janeway et al., ) consisting of many barriers and biological processes (Delves and Roitt, ). The immune system can be subdivided into innate immunity and adaptive immunity. The innate immunity is trigged when pathogens are identified by their pathogen associated molecular patterns (PAMPs) or when cells signal in response to damage, injury, or stress (Takeuchi and Akira, 2009). Although the innate system is non-specific and does not confer long-lasting protection (Mackay et al., ) it is the major defense mechanism against pathogens in most organisms (Litman et al., ). It consists of physical and chemical barriers including phagocytes and dendritic cells (DC), inflammation, the complement system, and natural killer cells. In contrast, the adaptive immunity relies on antigens and is highly specific to pathogens or pathogen-infected cells (Dörner and Radbruch, ). Lymphocytes are key role players in adaptive immunity and include both T cells and B cells (Janeway et al., ). Of the various components of the immune system the following are critical in clearance of viral infections; natural killer cells, interferons, dendritic cells, B cells, and T cells (Aoshi et al., ).
The immune system can be modulated by various factors including prostaglandins (PGs) (Harris et al., ). Prostaglandins are lipid molecules, derived from arachidonic acid (AA) and are produced by cyclooxygenase (COX), and PG synthases (Phipps et al., 1991). One of the most studied PGs is prostaglandin E2 (PGE2) which is produced by many cells including fibroblasts, macrophages and some malignant cells (Harris et al., ). PGE2 regulates various processes in the body via PGE2 receptors (EP1–EP4) (Sugimoto et al., 2000). Both the innate and adaptive immunity can also be regulated by the levels of PGE2, which can either have adverse or beneficial effects on the immune system's ability to fend off pathogens (Kalinski, ). This review focuses on the regulatory role of PGE2 on the immune system in the course of some well- viral infections caused by herpes simplex virus, Epstein-Barr virus, rotavirus, influenza A viruses, human immunodeficiency virus and hepatitis B virus, and the development of related potential therapies for the treatment of these infections.
Production and function of PGE2
Prostaglandins are eicosanoids that are produced by nearly all mammalian cells (Park et al., 2006). They are not stored within cells but rather produced in response to specific trauma, signaling molecules or stimuli such as infections (Smith, 1989; Funk, ). PGE2 is the most abundant prostanoid (Serhan and Levy, 2003) in the mammalian body and under normal physiological conditions and plays a role in regulation of immune responses, blood pressure, gastrointestinal integrity, fertility (Ricciotti and FitzGerald, 2011), and inflammation (Davies et al., ).
Biosynthesis of PGE2
Phospholipase A2, the rate-limiting enzyme in PGE2 synthesis
PGE2 synthesis is initiated with the liberation of AA (a polyunsaturated fatty acid) from membrane phospholipids, by phospholipase A2 enzymes (PLA2) (Funk, ) (Figure 1A). Phospholipase A2 enzymes are divided into three major classes: Secreted PLA2 (sPLA2), intracellular group VI calcium-independent PLA2 (GVl iPLA2) and group IV cytosolic PLA2 (GIV cPLA2) (Murakami and Kudo, ). While all PLA2 enzymes can release AA from membrane phospholipids, only cPLA2α (a family member of GIV cPLA2) performs this reaction as a primary function (Leslie, ; Murakami and Kudo, ). Cytosolic phospholipase A2α has been found in most cells and tissues and is highly specific for the sn-2 bond of AA.
Figure 1
Production of PGH2, the precursor to prostanoids
Cyclooxygenases (Figure 1C) are membrane-bound heme-containing glycoproteins that have two major functions, namely the addition of a 15-hydroperoxy group to AA to form prostaglandin G2 (PGG2) and the reduction of the nascent hydroperoxy group of PGG2 to form prostaglandin H2. Cyclooxygenase has two isoforms COX-1 (constitutively expressed) and COX-2 (inducible). Although they are similar in structure and function, COX-2 utilizes endogenous AA while COX-1 uses AA derived from exogenous sources such as dietary intake (Park et al., 2006).
Prostaglandin E2 synthases
Prostaglandin H2(PGH2) is the substrate for prostaglandin E synthases (PGES) which produces the more stable prostanoid, PGE2 (Zurier, 2014) (Figure 1D) as well as for prostanoid synthases (Figure 1E). The production of PGE2 requires at least three PGESs, microsomal prostaglandin E synthase-1 (mPGES-1), mPGES-2 and cytosolic prostaglandin E synthase (cPGES) (Figure 1E). For a detailed review on PGES the reader is referred to Park et al. (2006).
Degradation
PGE2 is rapidly degraded in vivo by 15-hydroxyprostaglandin dehydrogenase and is therefore rapidly removed from tissues and circulation (Förstermann and Neufang, ; Tai et al., 2002).
Prostaglandin E2 transport
Since PGs are produced intracellularly they need to be secreted to exert their extracellular effects (Park et al., 2006). The original prevailing notion was that newly synthesized PGs simply exited the cell via passive diffusion, as the electronegative interior of the cell favors the diffusion out of the cell (Schuster, 2002). However, the kinetics behind PG transport cannot be fully explained by this slow diffusion and a prostaglandin transporter (PGT) (Kanai et al., ) and multidrug resistance protein-4 (MRP4) (Reid et al., 2003) were found to import and export PGs, respectively. The prostaglandin transporter is a membrane spanning protein that is only expressed in prostanoid producing cells (Bao et al., ), while MRP4 is also a membrane spanning protein but is expressed in all cells (Russel et al., 2008).
Prostaglandin receptors and signaling
There are four PGE2 receptors, EP1, EP2, EP3, and EP4 (Figure 2). EP3 has several splice variants, adding an additional functional level to the receptor (Hata and Breyer, ). Of these four receptors, EP3 and EP4 have a higher affinity for PGE2 and thus require significantly lower concentration of PGE2 for effective signaling, compared to EP1 and EP2 (Kalinski, ). EP2 and EP4 mediate the anti-inflammatory and suppressive activity of PGE2 by signaling through Gs-coupled receptors, mediated by the adenylate cyclase-triggered cAMP/ PKA/CREB pathway (Fujino et al., ). While EP2 and EP4 share the same function, they are triggered by different concentrations of PGE2, allowing EP2 to mediate PGE2 functions over a longer time period and at a later stage of inflammation while EP4 is rapidly desensitized (Nishigaki et al., 1996). Although EP2 and EP4 signal in a cAMP-dependent manner, both have been shown to activate the GSK3/β-catenin pathway (Fujino et al., ). EP4 is also capable of signaling via the ERK1/2 pathway (Fujino et al., ). The signaling cascades of the EP receptors leads to the production of cAMP or the mobilization of Ca2+ which in turn leads to inflammation, pain, immunoregulation, mitogenesis and cell injury. EP1 and EP3 are not dependent on Gs- coupled receptors and lack any cAMP-activating functions. Instead, EP3 has cAMP-inhibiting functions. EP1 signals via Ca2+ release (Hata and Breyer, ) while most of the splice variants of EP3 signal via Gi-coupled PGE2 receptors and some Gs-coupled (Sugimoto et al., 1992). The differences between the various PGE2 receptors allow for adaptable patterns and responses of various cells types at certain stages in immunity (Kalinski, ). The reader is referred to Dennis and Norris ()for an in-depth review of eicosanoid signaling in infection and inflammation.
Figure 2
Viral immunity
The innate immune system is critical for pathogen recognition (Mackay et al., ) and functions as the first level of defense. In general the immune system relies upon leukocytes, antibodies, the complement system and cytokines to remove pathogens or toxins from the host (Janeway et al., ). Leukocytes are subdivided into different types, namely neutrophils, eosinophils, basophils, lymphocytes and monocytes which are distinguished by their physical and functional characteristics. Of particular importance to this review are the lymphocytes, which can be divided into B cells, T cells and natural killer cells, as well as monocytes which differentiate into macrophages in resident tissues. Antibodies are produced by plasma cells (differentiated B-cells) in response to specific antigens and bind to antigens. They bind to antigens, before the complexes are phagocytized. The complement system enhances the ability of antibodies and phagocytic cells to remove pathogens and damaged cells from an organism and promotes inflammation (Figure 3I). Although the complement system is considered to be part of the innate immune systems, it can be brought into action by the adaptive immune system. The complement system is known to consist of three components. These include, the classical pathway (relies on the activation of C1-complex by antibodies), the alternative pathway (relies on direct interaction between the pathogen and C3b) and the lectin pathway (relies on binding of certain sugars to mannose-binding lectin). Lastly, cytokines are a group of small molecules that are important in cell signaling and some as immunomodulatory agents. Cytokines play an important role in the balance between humoral and cell-based immunity.
Figure 3
Immune defenses against viruses are initiated when viral infection occurs or when antibodies from a previous infection recognize the virus and neutralize it (Mackay et al., ) (Figure 3A). Natural killer (NK) cells (Brandstadter and Yang, ) and interferons (IFN) are the most effective mechanism of the innate immunity against viral infections (Figures 3B,C). Natural killers cells are particularly important for the defense against the herpesvirus, poxvirus, papillomavirus, cytomegalovirus, influenza A virus, and human immunodeficiency virus (HIV) (Biron et al., ; Orange, 2002; Jost and Altfeld, ). These cells function mainly by killing infected cells by releasing cytotoxins early in infection, preventing spread to neighboring cells (Vivier et al., 2008). They also play a critical immunoregulatory role during the development of adaptive immunity. Thus, NK cell-mediated immunity plays a role in the control and clearance of viruses in the early stages of infection, but the continual stimulation of NK cells can contribute to viral pathology (Jost and Altfeld, ). However, there is still limited knowledge about the mechanisms of NK recognition and antiviral function. Another important response of the innate immunity toward viral infection is IFN (Samuel, 2001). Interferons are produced when a virus infects a cell (Sonnenfeld and Merigan, 1979). They are secreted as cell surface receptors causing the transcription of multitudes of IFN-stimulated genes which encode for protein products with antiviral, antimicrobial, antitumor and immunomodulatory effects (Fensterl and Sen, ). Type I (IFN-α, -β, -ω, -ϵ, -κ, -τ, -δ, -ν, and -ζ) and type III (IFN-λ) IFNs are induced when any cell recognizes PAMPs whereas type II (IFN-γ) is induced by other cytokines like IL-12 and expression is restricted to T cells and NK cells (Samuel, 2001; Fensterl and Sen, ). Viruses have also acquired various mechanisms to circumvent these actions of the innate immunity (Cerwenka and Lanier, ; Katze et al., ).
Another critical role player in innate immunity is a class of proteins called Toll-like receptors (TLRs) (Figure 3H; Xagorari and Chlichlia, 2008). Toll-like receptors are single, membrane spanning, non-catalytic receptors that are mainly expressed by macrophages and DCs. They are responsible for recognizing and responding to the PAMPs, leading to the activation of intracellular signaling pathways and altered gene expression. In turn, this allows the host immune system to detect pathogens and respond to their stimuli (Kawai and Akira, ). The signaling pathways that are activated by TLRs are responsible for the production of type I IFN, inflammatory cytokines and chemokines as well as the induction of immune responses responsible for eliminating pathogens (Kawai and Akira, ). Toll-like receptors signal via two distinct pathways, the MyD888-dependent and the TRIF-dependent pathways (Kawai and Akira, ). The MyD888-dependent pathway's primary effect is to activate nuclear factor kappa B (NFκB) and mitogen-activated proteins kinases, while activation of the TRIF-dependent pathway leads to the production of type I IFN and the transcription of NFκB. Sensing via TLRs is also responsible for the induction of DC maturation, which in turn initiates adaptive immune responses (Pasare and Medzhitov, 2004).
Dendritic cells and their system of antigen-presenting cells (APC) (Figures 3D,E) are another important component of immunity as they bridge the innate and adaptive immunity (Banchereau and Steinman, ; Chan et al., ). The main function of DCs are to activate naïve T cells by presenting processed antigen material on their surface (Banchereau and Steinman, ). However, before DCs can present the antigenic material, they have to complete a maturation cycle which is induced by either direct contact with pathogens or by interactions with other innate immune cells. Invading pathogens are sensed via extensive PAMP receptors which control the secretion of cytokines, migration, proliferation, and expression of major histocompatibility complex (MHC) II and co-stimulatory molecules in DCs (Steinman, 2003). The activation of DCs can be enhanced by activated NK cells (Chan et al., ).
The adaptive immunity's B and T cells are stimulated by DCs (Hess et al., ) (Figure 3G). B cells, which are the precursors to antibody secreting cells, directly recognize antigens through their B-cell receptors, while T cells are dependent on APCs for antigen recognition (Banchereau and Steinman, ). In viral infections, B cells (part of humoral immunity) begin their maturation process when they come in contact with viral antigens within the lymphatic system (Dörner and Radbruch, ). Naïve B cells have membrane-bound antibodies that effectively bind the viral antigen. Immediately following its contact with a specific viral antigen the B cell divides to become B memory cells and/or plasma cells. B memory cells express the same membrane-bound antibody as original naïve B cells and this is essential for a faster immune response to the particular viral antigen in future infections. Plasma cells also produce the same antibody as the original B cell, but are secreted into the bloodstream and neutralize the viral pathogen. T cells (part of cell-mediated immunity) express T cell receptors (TCR) and either CD4+ or CD8+ receptors (Sant and McMichael, 2012). As stated earlier, T cells cannot recognize antigens without receptor molecules (either MHC I or MHC II) which are membrane-bound on APCs. T cells mature into T helper cells (TH), cytotoxic T cell (Tc), and T regulatory cells (Tregs). T helper cells express CD4+ receptors and are responsible for activation of Tc, B cells and other immune cells (Alberts et al., ) (Figure 3F). As mentioned earlier, TH function by producing either Th1 or Th2 responses (Figure 3F). T helper cells 1 are produced when DCs secrete IL-2 and IFN-γ cytokines. These Th1 cells then secrete their own cytokines (IFN-γ and TNF-β) which stimulate recruitment of other lymphocytes to inflammation areas, induce B cell antibody switching and activate Tc (Romagnani, 1992). The Th1 responses are thus essential for the removal of intracellular pathogens. T helper cells 2 are produced when APC present antigens to TCR along with costimulatory molecule B7, IL-4, and IL-2. T helper cells 2 then secrete their own cytokines (IL-4, IL-5, and IL-13) which promotes IgE production, blocks IFN-γ receptors, recruits and activates basophil and eosinophil leukocytes (Romagnani, 1992). The Th2 response is thus responsible for the control of extracellular pathogens. Cytotoxic T cells remove pathogens and infected host cells and express CD8+ receptors, while Tregs express CD4+ and CD25+ and help in distinguishing of self from non-self-molecules (Alberts et al., ).
The role of PGE2 in inflammation and immunity
All the classic signs of inflammation (swelling, redness, heat, and pain) can be attributed to PGE2 (Funk, ). PGE2 causes redness and edema (of skin) by augmenting arterial dilation and microvascular permeability, increasing the blood flow into inflamed tissues. The pain caused by PGE2 results from the action on peripheral sensory neurons and on central sites within the spinal cord and brain. In addition, the binding of PGE2 to one of its various receptors can regulate the functions of macrophages, dendritic cells (DCs) and T and B lymphocytes (Ricciotti and FitzGerald, 2011). These regulating functions of cell types can in turn lead to both pro- and anti-inflammatory effects.
PGE2 also plays a role in the regulation of cytokine expression in DCs and has shown bias in T cell differentiation toward either Th1 or Th2 responses (Kirkpatrick, ) (Figure 4). Disruption in the early stages of DC differentiation is noted as one of the effects of PGE2 on DCs (Kalinski et al., ). In addition to the suppressive function of PGE2 on differentiation of functionally competent Th1-inducing DCs, they also suppress responses of Tc (Obermajer et al., 2011). The induction of the DC migratory phenotype permitting their homing to drain lymph nodes, is enhanced by PGE2 (Kabashima et al., ; Legler et al., ). During early maturation, PGE2 can stimulate DCs to express co-stimulatory molecules which enhance T-cell activation (Krause et al., ). PGE2 can also enhance DC production of suppressive factors, but the net effect on DCs is to enhance promotion of T cell expansion (Kalinski, ). Dendritic cells that have matured in the presence of PGE2 have an impaired ability to induce Th1 while enhancing Th2 responses. PGE2 also has suppressive effects on naïve T cell activation and expansion as well as direct inhibitory effects on interleukin 12 (IL-12) production and the expression of IL-12 receptors (Kalinski, ). Furthermore, PGE2 also balances the Th cell responses by inhibiting interferon (IFN)-γ, a Th1 response. It does, however, not inhibit IL-4 and IL-5, Th2 responses, in CD4+ T cells (Snijdewint et al., 1993) (Figure 4). PGE2 is responsible for the suppression of IL-2 production and IL-2 responsiveness in T cells, leading to the suppression of T cell activation and proliferation at high doses (Kalinski, ). At lower doses PGE2 already shows a great modulatory effect on the shifting patterns of CD4+ T cell responses form the aggressive Th1 cells toward Th2 and Th17 cells that cause less tissue destruction. The Th1 suppressive effect of PGE2 also relies on the suppression of IL-12 in macrophages and DCs (van der Pouw Kraan, 1995; Kalinski, ). Thus, PGE2 shifts the immune response from Th1 to Th2, which leads to a reduced protective ability against intracellular pathogens (viruses and bacteria). In addition to the direct effect of PGE2 on Th1 immune cells, recent studies have showed the indirect effect of PGE2 in enhancing the development and activity of suppressive types of immune cells (Kalinski, ). PGE2 has been shown to promote the development of Tregs in both mice and humans (Baratelli et al., ). The EP2- and EP4-dependent induction of Tregs in murine cancer (Sharma et al., 2005) and skin UV irradiation (Soontrapa et al., 2011), have been shown to rely on COX-2 and PGE2. The Tregs have been shown to have with an role in human tumor tissues (Bergmann et al., ), The interaction between DCs and Tregs are also promoted by PGE2, suggesting a role in the promotion of the expansion of pre-existing Tregs (Muthuswamy et al., 2008). It has also been shown the PGE2 is involved in mediating the suppressive effect of Tregs (Mahic et al., ).
Figure 4
T helper cells 17 are important in the maintenance of mucosal barriers and the subsequent clearance of pathogens from these areas and have been implicated in autoimmune disorders and infectious diseases (Zambrano-Zaragoza et al., 2014). Cytokines such as IL-6, TGFβ, IL-21, and IL-23 are involved in the development of Th17 cells (Holzer et al., ). In addition, it has been shown that PGE2 plays a role in the differentiation and function of Th17 cells via cAMP and EP2/EP4 signaling (Boniface et al., ). Napolitani et al. (2009) concluded that PGE2 may dramatically influence the balance between the highly inflammatory IL-17 and the negative feedback loop exerted by IFN-γ. PGE2 accomplishes this by triggering the expression of EP2 and EP4 receptors on T cells, leading to a rapid increase in retinoic-acid-related orphan receptor-γt (controls T-cell precursors) and a decrease of T-cell specific T-box transcription factor 21 mRNA (encodes for a Th1 cell-specific transcription factor). The role Th17 plays in viral infection will be discussed in detail in a later section. Although no direct link has been found between PGE2 and autoimmune diseases, the role of Th17 cells have been reviewed in Zambrano-Zaragoza et al. (2014), implicating causative roles in Glioma, Multiple Sclerosis, Type 1 Diabetes and others. Since PGE2 can play a regulatory role in Th17 cell differentiation and functioning, it may be speculated to have some role in autoimmune diseases.
Toll like receptor 4 is well-known for its ability to recognize LPS and other ligands, including viral proteins, polysaccharides, and endogenous proteins (Brubaker et al., ). PGE2 has strong suppressive effects on LPS-induced IFN-β production at mRNA and protein levels in murine J774A.1 macrophages (Xu et al., 2008). This inhibitory effect is mediated through EP2 and EP4 which in turn activates the Epac/PI3K/Akt pathway. In contrast, PGE2 inhibits LPS-induced TNF-α by a PKA pathway independent of the Epac/PI3K/Akt pathway. Importantly, it was found that blocking COX activity in vivo resulted in higher concentrations of IFN-β post-LPS. Degraaf et al. () showed that PGE2 can decrease the expression of TLR4. The authors showed that the effect was not by regulation of TLR4 mRNA but rather by the inhibition of its translation. They concluded that this reduction was mediated by EP2-dependent cAMP activated by PKA. The reduction in TLR4 expression was enough to decrease the transcription and section of TNF-α alveolar macrophages in responses to LPS. This thus shows that lipid mediators can modulate TLR4-mediated immune responses.
PGE2 can also interfere with early B cell activation and play a cAMP-mediated role in the regulation of immunoglobulin (Ig) class switching in B cells (Simkin et al., 1987; Phipps et al., 1991). Antibody class switching is a process where B cells change the production of antibodies from one type to another by a mechanism called class switch recombination (reviewed in Stavnezer and Amemiya, 2004). One of the most important consequences of these effects is the promotion of IgE production by PGE2 contributing to atopic disease (Carini et al., ).
Furthermore, PGE2 can also exert anti-inflammatory effects on neutrophils, macrophages, mast cells and NK cells which all form part of the innate immune system (Kalinski, ) (Figure 4). In NK cells, PGE2 functions by suppressing the responsiveness of IL-12 (Walker and Rotondo, 2004) and IL-15 (Joshi et al., ) which suppresses the cytolytic effects of NK cells (Bankhurst, ). PGE2 abrogates NK cell “helper” function by inhibiting the ability of NK cells to produce IFN-γ (Mailliard et al., ). The function of macrophages are modulated by PGE2 in an EP2-dependent (Aronoff et al., ) and phosphatase and tensin homolog-dependent manner (Canetti et al., ) which limits phagocytosis by alveolar macrophages and their pathogen-killing function (Serezani et al., 2007). This inhibition is in part mediated by induction of IL-1R–associated kinase-M, which blocks the scavenger receptor-mediated phagocytosis and the TLR-dependent activation of tumor necrosis factor-α (Hubbard et al., ). Furthermore, it has been shown that PGE2 in combination with LPS can promote anti-inflammatory phenotypes in macrophages by high expression of IL-10 and regulatory markers, SPHK1 and LIGHT, via a protein kinase A-dependent pathway (MacKenzie et al., ). The local attraction and degranulation of mast cells are induced by PGE2 in a mechanism involving EP1 and EP2 (Hu et al., ; Gomi et al., ).
Various steps of inflammation can thus be modulated by PGE2 in either a pro-inflammatory or anti-inflammatory manner. PGE2 can also modulate the immune system by shifting Th responses and thus affect the interplay between innate and adaptive immunity.
Viral infection and PGE2
As reviewed above, PGE2 has varying effects on the immune system. In some instances viruses can interact with PGE2 and possibly benefit from the effects of PGE2 (Table 1). A few of the potential effects of PGE2 on various viral infections are described:
Table 1
| Group | Virus | The effect of PGE2 on viral replication | Reference |
|---|---|---|---|
| (I) Double-stranded DNA viruses | Herpes simplex virus | Increase viral replications | Harbour et al., |
| Cytomegalovirus | PGE2 contributes to immunosuppressive effect | Nokta et al., 1996 | |
| PGE2 upregulation of major immediate promotor | Kline et al., | ||
| COX inhibitors decrease progeny virus but the effect is overcome by exogenous PGE2 | Zhu et al., 2002 | ||
| PGE2 increase plaque formation and viral DNA copy numbers | Hooks et al., | ||
| PGE2 plays a role in direct cell-to-cell spreading | Schröer and Shenk, 2008 | ||
| Epstein Barr virus | Lytic reaction via EP signaling pathways | Gandhi et al., | |
| (III) Double-stranded RNA viruses | Rotavirus | COX inhibitors reduce duration of diarrhea | Yamashiro et al., 1989 |
| PGE2 might contribute to pathogenicity | Zijlstra et al., 1999 | ||
| PGE2 and COX-activity essential for Wa strain infection | Rossen et al., 2004 | ||
| Might be required for early infection i.e. attachment | Rossen et al., 2004 | ||
| (IV) (+) Single-stranded RNA viruses | Coxsackie virus | Decrease viral titers | Xie et al., 2012 |
| Enterovirus 71 | PGE2 might be required for replication | Tung et al., 2010a, 2011; Wang et al., 2015 | |
| Sapovirus | PGE2 decreases the production of NO, leading to an increase in PSAV | Alfajaro et al., | |
| (V) (−) Single-stranded RNA viruses | Vesicular stomatitis virus | COX inhibitors/antagonist reduced viral production but the effect is overcome by exogenous PGE2 | Chen et al., |
| COX-2 antagonist decreased viral titers | Chen et al., | ||
| Influenza A virus | PGE2 has an inhibitory effect on innate and adaptive immunity in mice | Liu et al., | |
| PGE2 induces pro-inflammatory genes | Coulombe et al., | ||
| PGE2 activates expression of IL-27 | Park et al., 2016 | ||
| Parainfluenza 3 virus | PGE2 inhibits viral replication | Luczak et al., | |
| Lymphocytic choriomeningitis virus | PGE2i ihibits the survival and effector functions of Tc | Chen J. H. et al., | |
| Respiratory syncytial virus | PGE2 causes a delayed protective RSV specific immune response | Bartz et al., | |
| COX inhibitors reduced PGE2-dependent RNA transcription | Liu et al., | ||
| (VI) Single-stranded RNA-RT viruses | Human T-lymphotropic virus type III | PGE2 causes an increased production of virus | Kuno et al., |
| Human immunodeficiency virus | PGE2 enhances HIV-1 long terminal repeat mediated reporter gene activation | Olivier and Tremblay, 1998 | |
| PGE2 decreases virion penetration by suppressing expression of CCR5 | Thivierge et al., 1998 | ||
| PGE2 inhibits virus replication by protein kinase A-dependent mechanism | Hayes et al., | ||
| PGE2 has an immunosuppressive effects when co-infected with HPV | Fitzgerald et al., | ||
| PGE2 reduces cell-to-cell spreading | Clemente et al., | ||
| PGE2 could play a role in pathogenicity via Th17 cell regulation | Zambrano-Zaragoza et al., 2014 | ||
| (VII) Double-stranded DNA-RT viruses | Hepatitis B virus | PGE2 results in loss of viral replication | Flowers et al., |
| PGE2 decreases viral antigen | Hyman et al., | ||
| PGE2 could play a role in pathogenicity via Th17 cell regulation | Yang et al., 2013 |
The effect of PGE2 on viral replication and infection.
Double-stranded DNA viruses
Herpes simplex virus
Harbour et al. () showed that when African green monkey kidney epithelial cells (Vero cells) were treated with PGE2 (0.1 to 10 μg/ml) for 24 h prior to infection by herpes simplex virus (HSV) type I (SC.I6 strain), there was a significant increase in the size of the plaques. When a low multiplicity of infection (MOI) (0.1) was used, PGE2 increased the viral yield, while no such effect was seen at high MOI (10). Furthermore, when Vero cells were treated with PGE2 inhibitors (mefenamic acid and indomethacin) there was a decrease in plaque size and inhibition of viral replication at a low MOI. This inhibitory effect can be overcome by the addition of exogenous PGE2. Taken together the results indicate that PGE2 does not increase viral production, but rather enhances the spread of the virus between cells. Work done by Thiry et al. (1985) on bovine herpes virus 1 (IBR/Cu5 strain) in Georgia bovine kidney cells (GBK cells) also showed an increase in the mean plaque size when GBK cells were treated with 0.1 and 10 μg/ml of PGE2. Treatment of HSV-tk (herpes simplex virus thymidine kinase)-transduced MC38 (murine colon cancer) cells with sulfasalazine (a NFκB inhibitor) lead to the inhibition of NF-κB activity, inhibitor-κB phosphorylation and nuclear translocation of NF-κB (Konson et al., ). This significantly decreased COX-2 expression and in turn reduced PGE2 release. In addition, these authors found that HSV-tk-transduced 9L (rat gliosarcoma) and T24 (human urinary bladder cancer) cells enhanced the expression of COX-2 and significantly increased PGE2 levels. When 4T1 (mouse mammary tumor cells) cells were infected with OSVP (a murine 15-PGDH inserted into the OSV viral genome) expression cassette) there was a significant decrease in PGE2 accumulation which led to the alleviation of immune suppression in mice (Walker et al., 2011). It can thus be concluded that PGE2 plays a role in HSV infection, although the exact mechanisms by which it facilitates viral replication and release are yet to be elucidated.
Cytomegalovirus
The infection of human T lymphocyte cells (MO cells) with cytomegalovirus (CMV) (AD169 strain) was found to induce the release of PGE2 via a TNF-α-dependent pathway (Nokta et al., 1996). This release of PGE2 apparently contributes to the immunosuppressive effects of CMV and could be involved in the pathogenesis of CMV. Kline et al. () found that PGE2 can upregulate the major immediate promotor of human CMV (HCMV). They postulated that PGE2 could directly activate this promoter. Monocytoid cells (THP-1) were transfected with a plasmid containing the major immediate promoter gene and subsequently stimulated with PGE2. A synergistic increase in the promoter's activity was seen for PGE2 and other cytokines (IL-1β, TNF-α, IL-6, and IL-10). Human CMV may thus be activated by a mechanism which involves the activation of macrophages by these cytokines. The inhibition of COX-2 blocks the replication of HCMV, but when PGE2 is added exogenously the yield of infectious virus is substantially restored (Zhu et al., 2002). Hooks et al. () showed that retinal pigment epithelial (RPE) cells infected with CMV induced COX-2 mRNA and protein synthesis increasing PGE2 levels. The increased levels of PGE2 enhanced CMV plaque formation and CMV DNA copy numbers. This indicates that PGE2 is required for the effective replication of HCMV, although the molecular mechanisms are yet to be elucidated. The treatment of CMV infected primary human foreskin fibroblast (HFF) with tolfenamic acid and indomethacin (inhibitors of COX) drastically reduced the direct cell-to-cell spread of CMV (Schröer and Shenk, 2008). The effect of these inhibitors is reversed by the addition of PGE2. This indicates that PGE2 is required for the effective replication of HCMV, although the molecular mechanisms are yet to be elucidated.
Epstein barr virus
Gandhi et al. () investigated the link between chronic inflammation and the induction of Epstein Barr virus (EBV) lytic reactivation. They found that the addition of lipopolysaccharides (LPS) to cells latently infected with EBV, upregulated the expression of COX-2 and increased PGE2. The elevated levels of COX-2 and PGE2 coincided with gp350 (EBV late lytic protein) synthesis and detection of EBV in cell culture supernatant. When NS-398 (COX-2 inhibitor) was added to the cells, there was a drastic decrease in the levels of virus detected in cell culture supernatant. The overexpression of COX-2 and PGE2 in infected cells also coincided with the overexpression of PGE2 receptors EP1 and EP4. The addition of chemical inhibitors of EP1 and EP4 reduced the lytic reactivation of EBV even when COX-2 levels were upregulated. Taken together these results indicate that COX-2 is responsible for the lytic reactivation of EBV via PGE2 and its signaling via EP1 and EP4 receptor.
Double-stranded RNA viruses
Rotavirus
Studies in infants found that there was an increase in PGE2 in both stool and plasma during rotavirus (RV) infection (Yamashiro et al., 1989). When these children were treated with a COX-inhibitor there was a reduction in the duration of diarrhea. Rotavirus infection also upregulates expression of both MHC I and MHC II in piglets (Zijlstra et al., 1999). Increases of CD8+ and CD4+ T-lymphocyte numbers were observed in the jejunum of piglets as well as elevated levels of PGE2. These observations suggested that PGE2 might contribute to RV pathogenicity. In 2009 Rodríguez and co-workers infected human Caucasian colon adenocarcinoma cells (Caco-2 cells) with RV and showed that the immunomodulators, IL-8, PGE2, and small quantities of TGF-β1, were released in RV infection Rodríguez et al. (2009). These immunomodulators are known to shift the T cell response to Th2 and may in part be responsible for the low number of T-cells in blood samples during RV infection. Infection of cells with RV is significantly inhibited when cells are treated with peroxisome proliferator-activated receptor gamma (PPARγ) and NSAIDs, indicating that RV has pro-inflammatory actions (Guererero et al., ). Moreover, PGE2 and COX-activity were shown to be essential for the establishment of RV (Wa strain) infection in Caco-2 cells (Rossen et al., 2004). Peroxisome proliferator-activated receptor gamma is responsible for the regulation of fatty acid storage and glucose metabolism. This inhibitory effect on RV indicates that fatty acids and their downstream products, like eicosanoids, may play a role in RV infection as it is well-known that RV associates with lipid droplets which is crucial for RV replication (Cheung et al., ). Rossen et al. (2004) postulated that PGE2 is necessary for early infection, most likely in viral protein synthesis and progeny production, rather than viral RNA production. The exact pathways behind these mechanisms remain unknown. It appears as if RV requires pro-inflammatory signaling for efficient replication, and that viral replication is inhibited by anti-inflammatory treatment (Guerrero and Acosta, ). There is a still a major gap in understanding the molecular mechanisms behind RV-induced inflammatory signaling.
(+) Single-stranded RNA viruses
Coxsackie virus
Henke et al. () showed that when human monocytes are infected with Coxsackie virus (B3 strain) (CVB3) they become activated and secrete cytokines. Higher levels of PGE2 and TNF-α were detected via ELISAs in infected cells compared to the uninfected cells. In 2011, Xie and co-workers showed that when anti-mouse IL-17antibody was added to block IL-17A (cardiac tumor-necrosis factor alpha) in BALB/c mice there was an increase in COX-2 proteins and PGE2 as well as a decrease in transforming growth factor beta (TGF-β) and TNF-α Xie et al. (2012). This was followed by a reduction in viral titers and decreased pathological scores. They also indicated that PGE2 and COX-2 play a role in viral myocarditis by being upregulated by IL-17A and TNF-α. The exact mechanistic role of these factors on CVB3 infection is yet to be elucidated.
Enterovirus 71
When rat brain astrocytic (RBA-1) cells are infected with enterovirus (strain 71) (EV71) they induce the expression of COX-2 and the subsequent release of PGE2 via c-Src/PDGFR/PI3K/Akt/p42/ p44 MAPK/c-Jun and NF-κB cascades (Tung et al., 2010b). Tung et al. (2010b) showed that human neuroblastoma (SK–N–SH) cells infected with EV71 also induced the expression of COX-2 and the production of PGE2 via a MAPKs (p42/p44 MAPK, p38 MAPK and JNK) and observed that the increase in PGE2 generation might be required for EV17 replication in infected cells. They postulated that EV17 replication by this COX-2/PGE2 mechanism may have an effect on the pathogenesis of central nervous system diseases. In 2011 Tung and co-workers found that the activation of the cAMP response element binding protein (CREB) in addition to the role of the c-Src/EGFR/p42/p44 MAPK signaling pathway in SK–N–SH cells were essential for EV71-induced COX-2 protein expression, COX-2 mRNA synthesis, and PGE2 production. They also found that PGE2 promoted further viral infection through EP2/EP4 receptors-cAMP signaling. Formononetin has been shown to reduce RNA and protein synthesis of EV71 in a dose dependent manner (Wang et al., 2015). This reduction was due to the inhibiting effects of formononetin on EV71-induced COX-2 expression and PGE2 production via the MAPKs pathway, including ERK, p38, and JNK.
Sapovirus
Alfajaro et al. () showed that porcine kidney cells (LLC-PK) infected with porcine sapovirus (PSaV) Cowden strain, lead to an increase in the amount of COX-2 mRNA and protein levels while only transiently increasing the levels of COX-1. The authors also showed that the blocking of COX-1 and COX-2, by either NSAIDs or siRNAs, lead to a significant decrease in PGE2 and subsequently a decrease in the replication of PSaV. The viral proteins (VPg and ProPol) was found to be associated with activation of the COXs/PGE2 pathway. Furthermore, they observed that pharmacological inhibitors of COX-2 lead to a drastic increase in the production of NO, which lead to the reduction in PSaV replication that could be restored by inhibiting nitric oxide synthase via N-nitro-L-Methyl-Arginine-ester. The experimental data show that the sapovirus replication cycle depend or rely on the interaction with PGE2.
(−) Single-stranded RNA viruses
Vesicular stomatitis virus
Chen et al. () found that when Chinese Hamster Ovary (CHO) cells, infected with vesicular stomatitis virus (VSV) (Indiana serotype), were treated with aspirin, indomethacin (COX inhibitors) and celecoxib (COX-2 antagonist) there was an inhibitory effect on VSV propagation. They also found an increase in NO, a known inhibitor of VSV. Furthermore, when PGE2 was added to the cultures there was a significant decrease in NO and increase in viral yield. This indicates that the products of COX have an antagonistic effect on NO production which is in part responsible for the increase of VSV. Studies in mice (specific pathogen-free male BALB/c AnTac) by Chen et al. () found that inhibition of COX-2 favors the Th1 response which lead to increased expression of nitric oxide synthase (NOS) -1 and that PGE2 also effects NOS. In addition they indicated that PGE2 might induce protein inhibitor of NOS (PIN) which binds to NOS-1 and prevents its activity. This indicates that PGE2 has a definite role in the propagation and infectivity of VSV, possibly through induction of PIN expression.
Influenza A virus
Influenza A virus (IAV) hyper induces the COX-2 and PGE2 production (Liu et al., ). The accumulation of PGE2 then activates a PKA-CREB signaling pathway, which in turn activates the IL-27/EB13 promotor, leading to the expression of IL-27. Interleukin-27 is responsible for the activation of signal transducer and activator of transcription 1 (STAT1) and STAT2 which inhibits viral replication (Owaki et al., 2008). Coulombe et al. () showed that PGE2 has an inhibitory effect on both the innate and adaptive immunity when mice (C57BL/6, Taconic 4175, and Rag1−/−) were infected with IAV (A/Puerto Rico/8/34). PGE2 inhibited the recruitment and activities of macrophages via both EP2 and EP4. This had inhibitory actions on the type l IFNs and apoptosis pathways. The suppression of PGE2, via genetic ablation of mPGES-1 or by the pharmacological inhibition, improved survival after IAV infection, while the addition of PGE2 reversed this effect. They also showed that PGE2 inhibited T cell mediated immunity and thus concluded that IAV hijacks the mPGES-1/PGE2 pathway to suppress both innate and adaptive immunity in an IFN dependent manner. In 2016 Park and co-workers showed that the inhibition of mPGES-1 had anti-influenza effects by inhibiting PGE2 production and suppressing the induction of pro-inflammatory genes (TNF-α, IL-8, CCL5, and CXCL10). This anti-influenza effects was reversed by the addition of exogenous PGE2. The specific mechanism(s) used by IAV to increase PGE2 and evade antiviral responses remain unknown.
Parainfluenza 3 virus
Luczak et al. () showed that addition of PGE2 concentrations of 0.1–10 μg/ml to parainfluenza 3 (PIV3) virus infected WISH cells, inhibited the replication of PIV3. They observed that the effect was the most prominent when PGE2 was present in the media throughout the replication cycle, compared to PGE2 being added before infection and 2 h post-infection. They postulated that PGE2 may affect the replication of PIV3 by influencing the growth of WISH cells.
Lymphocytic choriomeningitis virus
It has been shown that PGE2 can impair the survival and effector functions of Tc during chronic lymphocytic choriomeningitis virus (LCMV) infection (Chen J. H. et al., ). When PGE2 signaling was blocked either directly (deletion of EP2 and EP4) or systemically (deletion of mPGES-1 or COX inhibitors) there was an increase in antigen specific Tc numbers and cytokine production. Chen J. H. et al. () also found that the simultaneous inhibition of PGE2 and PD-1 signaling (programmed cell death signaling) during LCMV infection increased the numbers, function and viral control of Tc. They concluded that the comodulation of PGE2 and PD-1 signaling could be a therapeutic avenue in the treatment of certain chronic diseases.
Respiratory syncytial virus
Macrophages and DCs from newborns were infected with respiratory syncytial virus (RSV) and showed an increase in IL-10, IL-11, and PGE2 generation (Bartz et al., ). These authors concluded that PGE2 and the cytokines might contribute to the predominance of Th2 being produced by DCs during ongoing RSV infection. This in turn could explain the delayed protective RSV specific immune response. In 2005 Liu and co-workers showed that PGE2 is produced by human alveolar type II-like epithelial (A549) cells infected with RSV and that it is required for viral replication. They found that RSV infection induces a time-dependent increase in both COX-2 mRNA expression and protein synthesis and thus leads to the enhanced production of PGE2. Furthermore, when PGE2 production was inhibited by blocking COX-2 or cPLA2 activation, there was a significant reduction in RSV replication. They concluded that the reduction in RSV infection is partly due to a significant inhibition of RNA transcription. Walsh et al. (2016) showed that ibuprofen (a NSAID) can decrease PGE2 production during RSV infection in 5 to 6 week-old outbred pre-ruminant bottle-fed Holstein bull calves. The decrease in PGE2 production in turn modulated the immune responses and improved clinical outcomes. However, they also found that treatment with ibuprofen did not affect lung histopathology and lead to increased viral shedding. They concluded that RSV should thus be treated with both antivirals and immunodulators.
Single-stranded RNA-RT viruses
Human T-lymphotropic virus type III
Kuno et al. () investigated the direct effects of PGE2 on a T-cell line (MT-4 cells) when infected with type III human T-lymphotropic virus (HTLV-III) as well as on HTLV-III continuous-producer cells (Molt-4/HTLV-III cells). They found that PGE2 enhanced the production and release of infectious virus in a dose-dependent manner. They concluded that PGE2 or its metabolites may play a role in the activation of transcription/translation of HTLV-III integrated genes or in the maturation of infectious viral particles. It is unclear if PGE2 plays any role in early infection before the integration of HTLV-III genes.
Human immunodeficiency virus
In 1998 Olivier and Tremblay showed that PGE2 had a upregulating effect on the long terminal repeat (LTR) gene of human immunodeficiency virus type-l (HIV-l) in Jurkat E6.1 cells. HIV-1 protein expression is driven by HIV-1 LTR. They found that this activation of HIV-1 by PGE2 was transduced via both, NFKβ-dependent and –independent, signaling pathways. It was concluded that the secretion of PGE2 by macrophages in response to infection or inflammatory activators could induce signaling pathways that results in the activation of proviral DNA present in T cells latently infected with HIV-1. When PGE2 is added to macrophages 24 h prior to infection with HIV-1 the cells show resistance to infection (Thivierge et al., 1998). The increase in PGE2 leads to increased cAMP levels which in turn downregulate the expression of CCR5 (coreceptor for HIV-1 entry). This inhibitory effect has also been observed in the replication of both M- tropic HIV-1BAL and HIV-1 in monocyte-derived macrophages (MDM) and monocytic cell line (UI), respectively (Hayes et al., ). The inhibition appears to rely on the cAMP/PKA-dependent mechanism and functions at a gene expression level decreasing HIV mRNA. Hayes et al. () demonstrated that the regulation of inhibition by the cAMP/PKA-dependent mechanism is through HIV-1 promoter activity. Women infected with human papillomavirus and HIV-1 showed an increase in cervical COX-2 and elevated systemic PGE2 levels (Fitzgerald et al., ) which may account for the immunosuppressive effects observed in infected patients. Samikkannu et al. (2014) showed that AA and its metabolites and accompanying enzymes (PGE2 and COX-2, respectively) mediate the accelerative effect of cocaine on HIV infection by impairing possible immune functions. PGE2 can also act in the late stages of HIV-1's viral cycle (Clemente et al., ). Treatment with PGE2 increased the activity of Rab1 (molecular switches that regulate membrane traffic), decreased RhoA (associated with cytoskeleton regulation) activity, and subsequently reduced the polymerization of actin. Furthermore, viral assembly platforms enriched with group-specific antigen (Gag) were disrupted. Taken together these results led Clemente et al. () to conclude that PGE2 reduces the infectivity of HIV-1 by affecting the spread of virions from cell-to-cell. In addition Zambrano-Zaragoza et al. (2014) suggested that Th17 cells and the Th17/Treg balance could maintain HIV under control and could therefore play a role in the disease progression of AIDS (Brandt et al., ). The ratio of Treg/Th17 showed a negative correlation to viral plasma load (Chevalier et al., ), although Treg cells correlated positively with viral load before antiviral therapy (He et al., ). Antiretroviral treatment normalizes this ratio in HIV patients (Brandt et al., ; He et al., ). Thus, PGE2 appears to have both an inhibitory and stimulatory effect on the replication of HIV-1 depending on specific conditions and could play a role in HIV pathogenicity via the regulation of Th17 cells.
Double-stranded DNA-RT viruses
Hepatitis B virus
The treatment of recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation with PGE2 has had some beneficial effects (Flowers et al., ). PGE2, given intravenously, followed by oral therapy, arrested or ameliorated recurrent infection in 67% of treated patients. Flowers et al. () speculated that the mechanism of PGE2 interference might rely on its ability to stabilize cellular membranes and inhibit HBV binding and replication. Hyman et al. () also showed that PGE2 has a beneficial effect on chronic HBV, but no effect on chronic hepatitis C (HCV). Patients were treated with PGE2 for 6 months and 47% of patients suffering from chronic HBV showed a decrease in HBV viral parameters [serum HBV DNA and HBeAg (envelope antigen of hepatitis B)]. In 2009, Xie and co-workers found that celecoxib (COX-2 inhibitor) had potent inhibitory effects on the growth of hepatitis B virus X protein positive hepatocellular carcinoma cells (HepG2-X) (Xie et al., 2009). When exogenous PGE2 was added to HepG2-X cells the inhibitory effect of celecoxib was slightly overcome. The exact beneficial mechanism of PGE2 is still unknown. T helper 17 cells as well as the ratio of Treg/Th17 appear to have a crucial role in the occurrence, development and outcome of HBV (Sun et al., 2012; Xue-Song et al., 2012). Interleukin 17 (cytokine of Th17 cells) has been shown to be indispensable for HBVs antigen (HBsAg)-stimulated differentiation of CD4+ cells into Th17 (Yang et al., 2013). Thus, Th17 cells have been show to participate in the pathogenesis of liver damage associated with HBV (Yang et al., 2013). It could, thus, be plausible that levels of PGE2 may play a role in the pathogenicity of HBV via Th17 cell differentiation.
Prostaglandin E2 as a potential therapeutic target
The current review highlights the potential of the biosynthetic pathway of PGE2 (Figure 1) as a therapeutic target in viral infections. This is possible as PGE2 has been shown to play a role in various viral infection, by either having a stimulatory/inhibitory effect on the viral life cycle or host's immune system.
One of the first potential therapies is limiting the amount of AA (or FA that can be converted to AA) that is taken in up in the diet of an individual (Calder, , ). This can be done by limiting the amount of n-6 polyunsaturated fatty acids (PUFAs) (vegetable oils, animal sources) and rather ingesting n-3 PUFAs (fish oils, marine sources) which are preferentially converted into either docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA). They act by replacing AA as an eicosanoid substrate and inhibiting AA metabolism (directly) or altering the effects of inflammatory genes through effects on transcriptional activation (indirectly) (Calder, ). Although EPA also gives rise to eicosanoids, these have anti-inflammatory effects in contrast to AA-derived eicosanoids (Calder, ).
Both of the COX isoforms can also serve as a potential target as they are directly responsible for the downstream production of PGE2. Of the two isozymes, COX-2 is a more attractive target as COX-1 is constitutively expressed and particularly important in gastrointestinal protection (Hawkey, ). This means that COX-2 selective drugs are required to regulate the production of PGE2. These drugs include coxibs (celecoxib and rofecoxib), etodalac, meloxicam, and nimesulide. Coxibs function by binding to side pockets close to the COX-2 active site, while etodalac, meloxicam and nimesulide bind in the active site (Jackson and Hawkey, ). All of these selective inhibitors have some side effects and can only partially inhibit PGE2 production.
The next possible therapeutic targets include the PGES (Murakami and Kudo, ). Microsomal prostaglandin E synthase-1 is the most promising target as the deletion of mPGES-1 in animal and cells models leads to no severe adverse effects (Chen Y. et al., ). There are no known mPGES-1 inhibitors due to the fact that compounds are not stable or effective in cellular assays or animal models. The search for an appropriate inhibitor is further complicated by specific differences in rodent and human models as they differ in key amino acid residues of mpGES-1 active site. Inhibitors also need to overcome the challenge of the complex binding mechanisms of both cofactors and substrates. Although all of these enzymes are potential therapeutic targets, care should be taken in the way these targets are inhibited as several of the downstream products of the of the PGE2 biosynthetic pathway are required for normal physiological functioning. The effect of the target should also take into account the effect that lowering/increasing PGE2 level may have on preexisting autoimmune conditions or in causing such conditions.
Conclusions
In response to viral infections the host elicits a defense by activating inflammation and immunity. The activation of inflammation by viral infections leads to the production of PGE2 which has a modulatory role in immunity and other roles in normal cell physiology. In this review, viruses from specific classes including, double-stranded DNA viruses (HSV, CMV, EBV, MAV-1), double-stranded RNA viruses (RV), (+) single-stranded RNA viruses (CVB3, EV71, PSaV), (−) single-stranded RNA viruses (VSV, IVA, PIV3, LCMV, RSV), single-stranded RNA-RT viruses (HTLV-III and HIV-l) and double-stranded DNA-RT viruses (HBV) and their interaction with PGE2 were reviewed. PGE2 had either an inhibitory, stimulatory or in some cases a dual role in there viral replication cycles. The stimulation of viral pathogenicity (HSV, CMV, EBV, RV, CVB3, EV71, PSaV, VSV, LCM, RSV, and HTLV-III) occurred mainly by affecting the host immunity, viral transcription/translation, and/or viral replication, while the inhibition (PIV3 and HBV) affected viral replication itself. In the case of both IAV and HIV-1, PGE2 was shown to have both a stimulatory and inhibitory effect. Both these viral stimulations were dependent on immune suppression and gene expression, while the inhibitory effects were dependent on IL-27 expression (IAV) and inhibition of spreading (HIV-1). In many of the viral infections the effect of PGE2 was negated when inhibitors of PGE2 synthesis was added, but the effects were overcome by the addition of exogenous PGE2. Interestingly, it appears that Th17 cells have a regulatory role in retrovirus infections. In turn Th17 cells are regulated by PGE2 which might play an indirect role in these viral infections. There are a number of possible therapeutic targets in the PGE2 biosynthetic pathway, although more research into their effects and modes of actions are required. This paper suggest that it may be possible to design therapeutic strategies to target selective pathways in an effort to attenuate inflammation associated with virus infection.
When looking into the majority of studies included in this review, the effect that PGE2 has in viral infections seem to have been a coincidental discovery and not the primary objective of these studies. In some cases the discovery was noted, but not further investigated. There is, therefore, a major gap in our knowledge of the exactly role of PGE2 in viral infections. These gaps include, determining the exact signaling pathways that viruses might use to induce PGE2, the role that PGE2 can play in the induction of autoimmunity and clarifying the dependence of viral infections of PGE2. The underlying mechanisms should be further investigated to determine if viruses require PGE2 to enhance their pathogenicity or require PGE2 for optimal viral replication. Furthermore, light should be shed on the possible effect that the interplay between TLRs, PGE2 and its receptors may have on viral infections. Taken together these mechanisms could also shed light on other host-pathogen interactions and may facilitate selection or development of the more optimal therapies against viral infections.
Funding
The study was funded through the South African National Research Foundation (Grant No: 103395 to HO).
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer MR and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.
Statements
Author contributions
WS compiled the information, co-wrote the manuscript, and approved the final version submitted. HO and CP provided scholarly input in placing the literature into context, edited the manuscript, and approved the final version submitted.
Acknowledgments
The authors would like to thank Prof Ulrich Desselberger (Department of Medicine, University of Cambridge) for critical reading of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer MR and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.
References
1
AlbertsB.JohnsonA.LewisJ.RaffM.RobertsK.WalterP.. (eds.) (2002). Helper T Cells and lymphocyte activation, in Molecular Biology of the Cell (New York, NY: Garland Science).
2
AlfajaroM. M.ChoiJ.-S.KimD.-S.SeoJ.-Y.KimJ.-Y.ParkJ.-G.et al. (2017). Activation of COX-2/PGE2 promotes sapovirus replication via the inhibition of nitric oxide production. J. Virol.91:e01656–e01716. 10.1128/JVI.01656-16
3
AoshiT.KoyamaS.KobiyamaK.AkiraS.IshiiK. J. (2011). Innate and adaptive immune responses to viral infection and vaccination. Curr. Opin. Virol.1, 226–232. 10.1016/j.coviro.2011.07.002
4
AronoffD. M.CanettiC.Peters-GoldenM. (2004). Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J. Immunol.173, 559–565. 10.4049/jimmunol.173.1.559
5
BaltimoreD. (1971). Expression of animal virus genomes. Bacteriol. Rev.35, 235–241.
6
BanchereauJ.SteinmanR. M. (1998). Dendritic cells and the control of immunity. Nature392, 245–252. 10.1038/32588
7
BankhurstA. D. (1982). The modulation of human natural killer cell activity by prostaglandins. J. Clin. Lab. Immunol.7, 85–91.
8
BaoY.PucciM. L.ChanB. S.LuR.ItoS.SchusterV. L.et al. (2002). Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am. J. Physiol. Renal Physiol.282, F1103–F1110. 10.1152/ajprenal.00152.2001
9
BaratelliF.LinY.ZhuL.YangS.-C.Heuzé-Vourc'hN.ZengG.et al. (2005). Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J. Immunol.175, 1483–1490. 10.4049/jimmunol.175.3.1483
10
BartzH.Büning-PfaueF.TürkelO.SchauerU. (2002). Respiratory syncytial virus induces prostaglandin E2, IL-10 and IL-11 generation in antigen presenting cells. Clin. Exp. Immunol.129, 438–445. 10.1046/j.1365-2249.2002.01927.x
11
BergmannC.StraussL.ZeidlerR.LangS.WhitesideT. L. (2007). Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res.67, 8865–8873. 10.1158/0008-5472.CAN-07-0767
12
BironC. A.ByronK. S.SullivanJ. L. (1989). Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med.320, 1731–1735. 10.1056/NEJM198906293202605
13
BonifaceK.Bak-JensenK. S.LiY.BlumenscheinW. M.McGeachyM. J.McClanahanT. K.et al. (2009). Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med.206, 535–548. 10.1084/jem.20082293
14
BrandstadterJ. D.YangY. (2011). Natural killer cell responses to viral infection. J. Innate Immun.3, 274–279. 10.1159/000324176
15
BrandtL.ScientC.BenfieldT.MensH.ClausenL. N.KatzensteinT. L.et al. (2011). Low level of regulatory T Cells and maintenance of balance between regulatory T cells and Th17 cells in HIV-1 – infected elite controllers. J. Acquir. Immune Defic. Syndr.57, 101–108. 10.1097/QAI.0b013e318215a991
16
BrubakerS. W.BonhamK. S.ZanoniI.KaganJ. C. (2015). Innate immune pattern recognition: a cell biological perspective. Annu. Rev. Immunol.33, 257–290. 10.1146/annurev-immunol-032414-112240
17
CalderP. C. (2005). Polyunsaturated fatty acids and inflammation. Biochem. Soc. Trans.33, 423–427. 10.1042/BST0330423
18
CalderP. C. (2006). n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr.83, 1505S–1519S.
19
CalderP. C. (2010). Omega-3 fatty acids and inflammatory processes. Nutrients2, 355–374. 10.3390/nu2030355
20
CanettiC.SerezaniC. H.AtraszR. G.WhiteE. S.AronoffD. M.Peters-GoldenM. (2007). Activation of phosphatase and tensin homolog on chromosome 10 mediates theinhibition of FcγR phagocytosis by prostaglandin E,2. J. Immunol.179, 8350–8356. 10.4049/jimmunol.179.12.8350
21
CariniC.HudspithB. N.BrostoffJ. (1981). Effect of prostaglandins and cyclic nucleotides on growth and immunoglobulin secretion of two IgE myeloma cell lines. Br. J. Cancer43, 257–260.
22
CerwenkaA.LanierL. L. (2001). Natural killer cells, viruses and cancer. Nat. Rev. Immunol.1, 41–49. 10.1038/35095564
23
ChanC. W.CraftonE.FanH.-N.FlookJ.YoshimuraK.SkaricaM.et al. (2006). Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med.12, 207–213. 10.1038/nm1352
24
ChenJ. H.PerryC. J.TsuiY.-C.StaronM. M.ParishI. A.DominguezC. X.et al. (2015). Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat. Med.21, 327–334. 10.1038/nm.3831
25
ChenN.RestivoA.ReissC. S. (2002). Selective inhibition of COX-2 is beneficial to mice infected intranasally with VSV. Prostaglandins Other Lipid Mediat.67, 143–155. 10.1016/S0090-6980(01)00185-X
26
ChenN.WarnerJ. L.ReissC. S. (2000). NSAID treatment suppresses VSV propagation in mouse CNS. Virology276, 44–51. 10.1006/viro.2000.0562
27
ChenY.LiuH.XuS.WangT.LiW. (2015). Targeting microsomal prostaglandin E2 synthase-1 (mPGES-1): the development of inhibitors as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs). Med. Chem. Commun.6, 2081–2123. 10.1039/C5MD00278H
28
CheungW.GillM.EspositoA.KaminskiC. F.CourousseN.ChwetzoffS.et al. (2010). Rotaviruses associate with cellular lipid droplet components to replicate in viroplasms, and compounds disrupting or blocking lipid droplets inhibit viroplasm formation and viral replication. J. Virol.84, 6782–6798. 10.1128/JVI.01757-09
29
ChevalierM. F.PetitjeanG.Dunyach-RémyC.DidierC.GirardP.-M.ManeaM. E.et al. (2013). The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog.9:e1003453. 10.1371/journal.ppat.1003453
30
ClementeM. I.ÁlvarezS.SerramíM. J.Martínez-BonetM.Muñoz-FernándezM. Á. (2014). Prostaglandin E2 reduces the release and infectivity of new cell-free virions and cell-to-cell HIV-1 transfer. PLoS ONE9:e85230. 10.1371/journal.pone.0085230
31
CoulombeF.JaworskaJ.VerwayM.TzelepisF.MassoudA.GillardJ.et al. (2014). Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity40, 554–568. 10.1016/j.immuni.2014.02.013
32
DaviesP.BaileyP. J.GoldenbergM. M.Ford-HutchinsonA. W. (1984). The Role of arachidonic acid oxygenation products in pain and inflammation. Annu. Rev. Immunol.2, 335–357. 10.1146/annurev.iy.02.040184.002003
33
DegraafA. J.ZasłonaZ.BourdonnayE.Peters-GoldenM. (2014). Prostaglandin E2 reduces toll-like receptor 4 expression in alveolar macrophages by inhibition of translation. Am. J. Respir. Cell Mol. Biol.51, 242–250. 10.1165/rcmb.2013-0495OC
34
DelvesP. J.RoittI. M. (2000). The immune system. N. Engl. J. Med.343, 108–117. 10.1056/NEJM200007063430107
35
DennisE. A.NorrisP. C. (2015). Eicosanoid storm in infection and inflammation. Nat. Rev. Immunol.15, 511–523. 10.1038/nri3859
36
DörnerT.RadbruchA. (2007). Antibodies and B cell memory in viral immunity. Immunity27, 384–392. 10.1016/j.immuni.2007.09.002
37
FensterlV.SenG. C. (2009). Interferons and viral infections. BioFactors35, 14–20. 10.1002/biof.6
38
FitzgeraldD. W.BezakK.OcheretinaO.RiviereC.WrightT. C.MilneG. L.et al. (2012). The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev. Res.5, 34–40. 10.1158/1940-6207.CAPR-11-0496
39
FlowersM.SherkerA.SinclairS. B.GreigP. D.CameronR.PhillipsM. J.et al. (1994). Prostaglandin E in the treatment of recurrent hepatitis B infection after orthotopic liver transplantation. Transplantation58, 183–191.
40
FörstermannU.NeufangB. (1983). Elimination from the circulation of cats of 6-keto-prostaglandin E1 compared with prostaglandins E2 and I2. J. Pharm. Pharmacol.35, 724–728. 10.1111/j.2042-7158.1983.tb02878.x
41
FujinoH.SalviS.ReganJ. W. (2005). Differential regulation of phosphorylation of the cAMP response element binding protein following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol. Pharmacol.68, 251–259. 10.1124/mol.105.011833
42
FujinoH.WestK. A.ReganJ. W. (2002). Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J. Biol. Chem.277, 2614–2619. 10.1074/jbc.M109440200
43
FujinoH.XuW.ReganJ. W. (2003). Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J. Biol. Chem.278, 12151–12156. 10.1074/jbc.M212665200
44
FunkC. D. (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. Science294, 1871–1875. 10.1126/science.294.5548.1871
45
GandhiJ.GaurN.KheraL.KaulR.RobertsonE. S. (2015). COX-2 induces lytic reactivation of EBV through PGE2 by modulating the EP receptor signaling pathway. Virology484, 1–14. 10.1016/j.virol.2015.05.006
46
GomiK.ZhuF. G.MarshallJ. S. (2000). Prostaglandin E2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through an EP1/EP3-dependent mechanism. J. Immunol.165, 6545–6552. 10.4049/jimmunol.165.11.6545
47
GuerereroC. A.MurilloA.AcostaO. (2012). Inhibition of rotavirus infection in cultured cells by N-acetyl-cysteine, PPARγ agonists and NSAIDs. Antiviral Res.96, 1–12. 10.1016/j.antiviral.2012.06.011
48
GuerreroC. A.AcostaO. (2016). Inflammatory and oxidative stress in rotavirus infection. World J. Virol.5, 38–62. 10.5501/wjv.v5.i2.38
49
HarbourD. A.BlythW. A.HillT. J. (1978). Prostaglandins enhance spread of herpes simplex virus in cell cultures. J. Gen. Virol.41, 87–95. 10.1099/0022-1317-41-1-87
50
HarrisS. G.PadillaJ.KoumasL.RayD.PhippsR. P. (2002). Prostaglandins as modulators of immunity. Trends Immunol.23, 144–150. 10.1016/S1471-4906(01)02154-8
51
HataA. N.BreyerR. M. (2004). Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther.103, 147–166. 10.1016/j.pharmthera.2004.06.003
52
HawkeyC. J. (2001). COX-1 and COX-2 inhibitors. Best Pract. Res. Clin. Gastroenterol.15, 801–820. 10.1053/bega.2001.0236
53
HayesM. M.LaneB. R.KingS. R.MarkovitzD. M.CoffeyM. J. (2002). Prostaglandin E2 inhibits replication of HIV-1 in macrophages through activation of protein kinase A. Cell. Immunol.215, 61–71. 10.1016/S0008-8749(02)00017-5
54
HeY.LiJ.ZhengY.LuoY.ZhouH.YaoY.et al. (2012). A randomized case–control study of dynamic changes in peripheral blood Th17/Treg cell balance and interleukin-17 levels in highly active antiretroviral-treated HIV Type 1/AIDS patients. AIDS Res. Hum. Retroviruses28, 339–345. 10.1089/aid.2011.0140
55
HenkeA.SpenglerH.-P.StelznerA.NainM.GemsaD. (1992). Lipopolysaccharide suppresses cytokine release from coxsackie virus-infected human monocytes. Res. Immunol.143, 65–70.
56
HessN. C. L.CarlsonD. J.InderJ. D.JesulolaE.McfarlaneJ. R.SmartN. A. (2016). Clinically meaningful blood pressure reductions with low intensity isometric handgrip exercise. A randomized trial. Physiol. Res.65, 461–468. 10.1017/CBO9781107415324.004
57
HolzerU.ReinhardtK.LangP.HandgretingerR.FischerN. (2013). Influence of a mutation in IFN-γ receptor 2 (IFNGR2) in human cells on the generation of Th17 cells in memory T cells. Hum. Immunol.74, 693–700. 10.1016/j.humimm.2013.02.002
58
HooksJ. J.ChinM. S.SrinivasanK.MommaY.HooperL. C.NagineniC. N.et al. (2006). Human cytomegalovirus induced cyclooxygenase-2 in human retinal pigment epithelial cells augments viral replication through a prostaglandin pathway. Microbes Infect.8, 2236–2244. 10.1016/j.micinf.2006.04.010
59
HuZ. Q.AsanoK.SekiH.ShimamuraT. (1995). An essential role of prostaglandin E on mouse mast cell induction. J. Immunol.155, 2134–2142.
60
HubbardL. L. N.BallingerM. N.ThomasP. E.WilkeC. A.StandifordT. J.KobayashiK. S.et al. (2010). A role for IL-1 receptor-associated kinase-M in prostaglandin E2-induced immunosuppression post-bone marrow transplantation. J. Immunol.184, 6299–6308. 10.4049/jimmunol.0902828
61
HymanA.YimC.KrajdenM.ReadS.BasinskiA. S. H.WanlessI.et al. (1999). Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C. J. Viral Hepat.6, 329–336. 10.1046/j.1365-2893.1999.00161.x
62
JacksonL.HawkeyC. (2000). Cox-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages?Drugs59, 1207–1216. 10.2165/00003495-200059060-00001
63
JanewayC. A.Jr.TraversP.WalportM.ShlomchikM. J. (2004). Immunobiology : The Immune System in Health and Disease. 6th Edn. New York, NY: Garland Science.
64
JenkinsC. M.CedarsA.GrossR. W. (2009). Eicosanoid signalling pathways in the heart. Cardiovasc. Res.82, 240–249. 10.1093/cvr/cvn346
65
JoshiP. C.ZhouX. C.CuchensM.JonesQ. (2001). Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common gamma-chain. J. Immunol.166, 885–891. 10.4049/jimmunol.166.2.885
66
JostS.AltfeldM. (2013). Control of human viral infections by natural killer cells. Annu. Rev. Immunol.31, 163–194. 10.1146/annurev-immunol-032712-100001
67
KabashimaK.SakataD.NagamachiM.MiyachiY.InabaK.NarumiyaS. (2003). Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat.Med.9, 744–749. 10.1038/nm872
68
KalinskiP. (2012). Regulation of immune responses by prostaglandin E2. J. Immunol.188, 21–28. 10.4049/jimmunol.1101029
69
KalinskiP.HilkensC. M.SnijdersA.SnijdewintF. G.KapsenbergM. L. (1997). IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol.159, 28–35.
70
KanaiN.LuR.SatrianoJ. A.BaoY.WolkoffA. W.SchusterV. L. (1995). Identification and characterization of a prostaglandin transporter. Science268, 866–869. 10.1126/science.7754369
71
KatzeM. G.HeY.GaleM.Jr. (2002). Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol.2, 675–687. 10.1038/nri888
72
KawaiT.AkiraS. (2005). Pathogen recognition with TLRs. Curr. Opin. Immunol.17, 338–344. 10.1016/j.coi.2005.02.007
73
KawaiT.AkiraS. (2006). Innate immune recognition of viral infection. Nat. Immunol.7, 131–137. 10.1038/ni1303
74
KawaiT.AkiraS. (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol.11, 373–384. 10.1038/ni.1863
75
KirkpatrickP. (2005). Oestrogen activates COX2 pathway Blocking the route to infection. Discovery4, 485–487. 10.1126/science.1103333
76
KlineJ. N.HunninghakeG. M.HeB.MonickM. M.HunninghakeG. W. (1998). Synergistic activation of the human cytomegalovirus major immediate early promoter by prostaglandin E2 and cytokines. Exp. Lung Res.24, 3–14.
77
KonsonA.MahajnaJ. A.DanonA.RimonG.AgbariaR. (2006). The involvement of nuclear factor-kappa β in cyclooxygenase-2 overexpression in murine colon cancer cells transduced with herpes simplex virus thymidine kinase gene. Cancer Gene Ther.13, 1093–1104. 10.1038/sj.cgt.7700983
78
KooninE. V.SenkevichT. G.DoljaV. V. (2006). The ancient virus world and evolution of cells. Biol. Direct1:29. 10.1186/1745-6150-1-29
79
KrauseP.BrucknerM.UermösiC.SingerE.GroettrupM.LeglerD. F. (2009). Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood113, 2451–2460. 10.1182/blood-2008-05-157123
80
KunoS.UenoR.HayaishiO.NakashimaH.HaradaS.YamamotoN. (1986). Prostaglandin E2, a seminal constituent, facilitates the replication of acquired immune deficiency syndrome virus in vitro. Proc. Natl. Acad. Sci. U.S.A.83, 3487–3490.
81
LeglerD. F.KrauseP.ScandellaE.SingerE.GroettrupM. (2006). Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J. Immunol.176, 966–973. 10.4049/jimmunol.176.2.966
82
LeslieC. C. (2004). Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. Prostaglandins Leukot. Essent. Fatty Acids4, 373–376. 10.1016/j.plefa.2003.12.012
83
LitmanG. W.CannonJ. P.DishawL. J. (2005). Reconstructing immune phylogeny: new perspectives. Nat. Rev. Immunol.5, 866–879. 10.1038/nri1712
84
LiuL.CaoZ.ChenJ.LiR.CaoY.ZhuC.et al. (2012). Influenza A virus induces interleukin-27 through cyclooxygenase-2 and protein kinase A signaling. J. Biol. Chem.287, 11899–11910. 10.1074/jbc.M111.308064
85
LiuT.ZamanW.KaphaliaB. S.AnsariG. A. S.GarofaloR. P.CasolaA. (2005). RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication. Virology343, 12–24. 10.1016/j.virol.2005.08.012
86
LuczakM.GiymulkaW.SzlviigielskiS.Koi~beckiM. (1975). Inhibition of multiplieation of parainfluenza 3 virus in prostaglandin-treated WISH cells. Arch. Virol.49, 377–380.
87
MackayI. R.RosenF. S.MedzhitovR.JanewayC. (2000). Innate immunity. N. Engl. J. Med.343, 338–344. 10.1056/NEJM200008033430506
88
MacKenzieK. F.ClarkK.NaqviS.McGuireV. A.NöehrenG.KristariyantoY.et al. (2013). PGE2 induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J. Immunol.190, 565–577. 10.4049/jimmunol.1202462
89
MahicM.YaqubS.JohanssonC. C.TaskenK.AandahlE. M. (2006). FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J. Immunol.177, 246–254. 10.4049/jimmunol.177.1.246
90
MailliardR. B.AlberS. M.ShenH.WatkinsS. C. (2005). IL-18–induced CD83+ CCR7+ NK helper cells. October202, 941–953. 10.1084/jem.20050128
91
MurakamiM.KudoI. (2004). Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog. Lipid Res.43, 3–35. 10.1016/S0163-7827(03)00037-7
92
MurakamiM.KudoI. (2006). Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr. Pharm. Des.12, 943–954. 10.2174/138161206776055912
93
MuthuswamyR.UrbanJ.LeeJ.-J.ReinhartT. A.BartlettD.KalinskiP. (2008). Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res.68, 5972–5978. 10.1158/0008-5472.CAN-07-6818
94
NapolitaniG.Acosta-RodriguezE. V.LanzavecchiaA.SallustoF. (2009). Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-γ production by memory CD4+ T cells. Eur. J. Immunol.39, 1301–1312. 10.1002/eji.200838969
95
NasrallahR.HassounehR.HebertR. L. (2014). Chronic kidney disease: targeting prostaglandin E2 receptors. Am. J. Physiol. Ren. Physiol.307, F243–F250. 10.1152/ajprenal.00224.2014
96
NishigakiN.NegishiM.IchikawaA. (1996). Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol. Pharmacol.50, 1031–1037. 10.1254/fpj.108.supplement_65
97
NoktaM. A.HassanM. I.LoeschK.PollardR. B. (1996). Human cytomegalovirus-induced immunosuppression relationship to and prostaglandin E2 in human monocytes. J. Clin. Invest97, 2635–2641.
98
ObermajerN.MuthuswamyR.LesnockJ.EdwardsR. P.KalinskiP. (2011). Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood118, 5498–5505. 10.1182/blood-2011-07-365825
99
OlivierM.TremblayM. J. (1998). Prostaglandin E2 up-regulates HIV-1 long terminal repeat-driven gene activity in T cCells via NFκB-dependent and -independent signaling pathways. Mol. Biol.273, 27306–27314.
100
OrangeJ. S. (2002). Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect.4, 1545–1558. 10.1016/S1286-4579(02)00038-2
101
OwakiT.AsakawaM.MorishimaN.MizoguchiI.FukaiF.TakedaK.et al. (2008). STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J. Immunol.180, 2903–2911. 10.4049/jimmunol.180.5.2903
102
ParkJ. H.ParkE. B.LeeJ. Y.MinJ. Y. (2016). Identification of novel membrane-associated prostaglandin E synthase-1 (mPGES-1) inhibitors with anti-influenza activities in vitro. Biochem. Biophys. Res. Commun.469, 848–855. 10.1016/j.bbrc.2015.11.129
103
ParkJ. Y.PillingerM. H.AbramsonS. B. (2006). Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol.119, 229–240. 10.1016/j.clim.2006.01.016
104
PasareC.MedzhitovR. (2004). Toll-like receptors: linking innate and adaptive immunity. Microbes Infect.6, 1382–1387. 10.1016/j.micinf.2004.08.018
105
PhippsR. P.SteinS. H.RoperR. L. (1991). A new view of prostaglandin E regulation of the immune response. Immunol. Today12, 349–352. 10.1016/0167-5699(91)90064-Z
106
ReidG.WielingaP.ZelcerN.van der HeijdenI.KuilA.de HaasM.et al. (2003). The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl. Acad. Sci. U.S.A.100, 9244–9249. 10.1073/pnas.1033060100
107
RicciottiE.FitzGeraldG. A. (2011). Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol.31, 986–1000. 10.1161/ATVBAHA.110.207449
108
RodríguezL.-S.BarretoA.FrancoM. A.AngelJ. (2009). Immunomodulators released during rotavirus infection of polarized Caco-2 cells. Viral Immunol.22, 163–172. 10.1089/vim.2008.0110
109
RomagnaniS. (1992). Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int. J. Clin. Lab. Res.21, 152–158. 10.1007/BF02591635
110
RossenJ. W. A.BoumaJ.RaatgeepR. H. C.BüllerH. A.EinerhandA. W. C. (2004). Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step. J. Virol.78, 9721–9730. 10.1128/JVI.78.18.9721–9730.2004
111
RouseB. T.SehrawatS. (2010). Immunity and immunopathology to viruses: what decides the outcome?Nat. Rev. Immunol.10, 514–526. 10.1038/nri2802
112
RusselF. G. M.KoenderinkJ. B.MasereeuwR. (2008). Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci.29, 200–207. 10.1016/j.tips.2008.01.006
113
SamikkannuT.RaoK. V. K.DingH.AgudeloM.RaymondA. D.YooC.et al. (2014). Immunopathogenesis of HIV infection in cocaine users: Role of arachidonic acid. PLoS ONE9:e106348. 10.1371/journal.pone.0106348
114
SamuelC. E. (2001). Antiviral actions of interferons. Clin. Microbiol. Rev.14, 778–809. 10.1128/CMR.14.4.778-809.2001
115
SantA. J.McMichaelA. (2012). Revealing the role of CD4+ T cells in viral immunity. J. Exp. Med.209, 1391–1395. 10.1084/jem.20121517
116
SchröerJ.ShenkT. (2008). Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus. Proc. Natl. Acad. Sci. U.S.A.105, 19468–19473. 10.1073/pnas.0810740105
117
SchusterV. L. (2002). Prostaglandin transport. Prostaglandins Other Lipid Mediat. 68–69, 633–647. 10.1016/S0090-6980(02)00061-8
118
SerezaniC. H.ChungJ.BallingerM. N.MooreB. B.AronoffD. M.Peters-GoldenM. (2007). Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am. J. Respir. Cell Mol. Biol.37, 562–570. 10.1165/rcmb.2007-0153OC
119
SerhanC. N.LevyB. (2003). Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics. Proc. Natl. Acad. Sci. U.S.A.100, 8609–8611. 10.1073/pnas.1733589100
120
SharmaS.YangS.-C.ZhuL.ReckampK.GardnerB. (2005). Tumor cyclooxygenase-2 / prostaglandin E 2 − dependent promotion of FOXP3 expression and CD4 + CD25 + T regulatory cell activities in lung cancer. Cancer Res.65, 5211–5220. 10.1158/0008-5472.CAN-05-0141
121
SimkinN. J.JelinekD. F.LipskyP. E. (1987). Inhibition of human B cell responsiveness by prostaglandin E2. J. Immunol.138, 1074–1081.
122
SmithW. L. (1989). The eicosanoids and their biochemical mechanisms of action. Biochem. J.259, 315–324. 10.1042/bj2590315
123
SnijdewintF. G.KalińskiP.WierengaE. A.BosJ. D.KapsenbergM. L. (1993). Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol.150, 5321–5329.
124
SonnenfeldG.MeriganT. C. (1979). The role of interferon in viral infections. Springer Semin. Immunopathol.338, 311–338.
125
SoontrapaK.HondaT.SakataD.YaoC.HirataT.HoriS.et al. (2011). Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc. Natl. Acad. Sci. U.S.A.108, 6668–6673. 10.1073/pnas.1018625108
126
StavnezerJ.AmemiyaC. T. (2004). Evolution of isotype switching. Semin. Immunol.16, 257–275. 10.1016/j.smim.2004.08.005
127
SteinmanR. M. (2003). Some interfaces of dendritic cell biology. APMIS111, 675–697. 10.1034/j.1600-0463.2003.11107802.x
128
SugimotoY.NambasT.HondaA.HayashisY.NegishiM.IchikawaA.et al. (1992). Cloning and expression of a cDNA for mouse prostaglandin E Receptor EP3 Subtype. J. Biol. Chem.267, 6463–6466.
129
SugimotoY.NarumiyaS. (2007). Prostaglandin E receptors. J. Biol. Chem.282, 11613–11617. 10.1074/jbc.R600038200
130
SugimotoY.NarumiyaS.IchikawaA. (2000). Distribution and function of prostanoid receptors: studies from knockout mice. Prog. Lipid Res.39, 289–314. 10.1016/S0163-7827(00)00008-4
131
SunH. Q.ZhangJ. Y.ZhangH.ZouZ. S.WangF. S.JiaJ. H. (2012). Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J. Viral Hepat.19, 396–403. 10.1111/j.1365-2893.2011.01561.x
132
TaiH. H.EnsorC. M.TongM.ZhouH.YanF. (2002). Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 68–69, 483–493. 10.1016/S0090-6980(02)00050-3
133
TakeuchiO.AkiraS. (2009). Innate immunity to virus infection. Immunol. Rev.227, 75–86. 10.1111/j.1600-065X.2008.00737.x
134
ThiryE.MignonB.ThalassoF.PastoretP. P. (1985). Effect of prostaglandins PGE2 and PGF2α on the mean plaque size of bovine herpesvirus 1. Ann. Rech. Vet.16, 80–85.
135
ThiviergeM.Le GouillC.TremblayM. J.StankováJ.Rola-PleszczynskiM. (1998). Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: downregulation of CCR5 expression by cyclic adenosine monophosphate. Blood92, 40–45.
136
TungW. H.HsiehH. L.YangC. M. (2010a). Enterovirus 71 induces COX-2 expression via MAPKs, NF-κB, and AP-1 in SK-N-SH cells: Role of PGE2 in viral replication. Cell. Signal.22, 234–246. 10.1016/j.cellsig.2009.09.018
137
TungW. H.HsiehH. L.LeeI. T.YangC. M. (2011). Enterovirus 71 modulates a COX-2/PGE2/cAMP-dependent viral replication in human neuroblastoma cells: role of the c-Src/EGFR/p42/p44 MAPK/CREB signaling pathway. J. Cell. Biochem.112, 559–570. 10.1002/jcb.22946
138
TungW. H.LeeI. T.HsiehH. L.YangC. M. (2010b). EV71 induces COX-2 expression via c-Src/PDGFR/PI3K/Akt/p42/p44 MAPK/AP-1 and NF-κB in rat brain astrocytes. J. Cell. Physiol.224, 376–386. 10.1002/jcp.22133
139
van der Pouw KraanT. C. (1995). Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med.181, 775–779. 10.1084/jem.181.2.775
140
VivierE.TomaselloE.BaratinM.WalzerT.UgoliniS. (2008). Functions of natural killer cells. Nat. Immunol.9, 503–510. 10.1038/ni1582
141
WalkerJ. D.SehgalI.KousoulasK. G. (2011). Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice. J. Virol.85, 7363–7371. 10.1128/JVI.00098-11
142
WalkerW.RotondoD. (2004). Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-γ synthesis. Immunology111, 298–305. 10.1111/j.1365-2567.2004.01810.x
143
WalshP.BehrensN.ChaigneauF. R. C.McEligotH.AgrawalK.NewmanJ. W.et al. (2016). A randomized placebo controlled trial of Ibuprofen for respiratory syncytial virus infection in a bovine nodel. PLoS ONE11:e0152913. 10.1371/journal.pone.0152913
144
WangH.ZhangD.GeM.LiZ.JiangJ.LiY. (2015). Formononetin inhibits enterovirus 71 replication by regulating COX- 2/PGE2 expression. Virol. J.12, 35. 10.1186/s12985-015-0264-x
145
XagorariA.ChlichliaK. (2008). Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol. J.2, 49–59. 10.2174/1874285800802010049
146
XieH.GaoL.ChaiN.SongJ.WangJ.SongZ.et al. (2009). Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Mol. Carcinog.48, 56–65. 10.1002/mc.20455
147
XieY.ChenR.ZhangX.YuY.YangY.ZouY.et al. (2012). Blockade of interleukin-17A protects against coxsackievirus B3-induced myocarditis by increasing COX-2/PGE2 production in the heart. FEMS Immunol. Med. Microbiol.64, 343–351. 10.1111/j.1574-695X.2011.00918.x
148
XuX. J.ReichnerJ. S.MastrofrancescoB.HenryW. L.AlbinaJ. E. (2008). Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN- production. J. Immunol.180, 2125–2131. 10.4049/jimmunol.180.4.2125
149
Xue-SongL.Cheng-ZhongL.YingZ.Mo-BinW. (2012). Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection. BMC Gastroenterol.12:43. 10.1186/1471-230X-12-43
150
YamashiroY.ShimizuT.OguchiT.SatoM. (1989). Prostaglandins in the plasma and stool of children with rotavirus gastroenteritis. J. Pediatr. Gastroenterol. Nutr.9, 322–327.
151
YangB.WangY.ZhaoC.YanW.CheH.ShenC.et al. (2013). Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection. Immunol. Lett.149, 41–49. 10.1016/j.imlet.2012.12.001
152
Zambrano-ZaragozaJ. F.Romo-MartínezE. J.Durán-AvelarM.deJ.García-MagallanesN.Vibanco-PérezN. (2014). Th17 Cells in Autoimmune and Infectious Diseases. Int. J. Inflam.2014, 1–12. 10.1155/2014/651503
153
ZhuH.CongJ.-P.YuD.BresnahanW. A.ShenkT. E. (2002). Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc. Natl. Acad. Sci. U.S.A.99, 3932–3937. 10.1073/pnas.052713799
154
ZijlstraR. T.McCrackenB. A.OdleJ.DonovanS. M.GelbergH. B.PetschowB. W.et al. (1999). Malnutrition modifies pig small intestinal inflammatory responses to rotavirus. J. Nutr.129, 838–843.
155
ZurierR. B. (2014). Prostaglandins, leukotrienes, and related compounds, in Encyclopedia of Medical Immunology, eds MackeyI. R.RoseN. R.DiamondB.DavidsonA.(New York, NY: Springer New York), 905–916.
Summary
Keywords
inflammation, prostaglandin E2, immunity, viral infection, therapeutic agents
Citation
Sander WJ, O'Neill HG and Pohl CH (2017) Prostaglandin E2 As a Modulator of Viral Infections. Front. Physiol. 8:89. doi: 10.3389/fphys.2017.00089
Received
02 November 2016
Accepted
01 February 2017
Published
14 February 2017
Volume
8 - 2017
Edited by
Luigi Iuliano, Sapienza University of Rome, Italy
Reviewed by
Kristiaan Wouters, Maastricht University, Netherlands; Matteo A. Russo, Sapienza University of Rome, Italy
Updates
Copyright
© 2017 Sander, O'Neill and Pohl.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Carolina H. Pohl PohlCH@ufs.ac.za
This article was submitted to Lipidology, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.